Cited by 67Liver physiology and pathologyCardiovascular Conditions and TreatmentsToxic Organic Pollutants Impact

Liver Deformation in Ahr-Null Mice: Evidence for Aberrant Hepatic Perfusion In Early Development

Harstad, Eric B., Guite, Christopher A., Thomae, Tami L., Bradfield, Christopher A.·2006·Molecular Pharmacology

Abstract

Mice harboring mutations in the Ahr locus display a patent ductus venosus and smaller livers throughout life. We tested the hypothesis that these hepatic aberrations are secondary to a developmental defect in hepatovascular blood flow by performing a detailed analysis of hepatic development in wild-type and Ahr-/- mice. This study revealed necrotic lesions in the peripheries of Ahr-/- fetal livers as early as embryonic day 15.5, with an increasing incidence up to postnatal day 1 and resolution by 2 weeks post partum. To visualize perfusion of fetal livers, we injected fluorescein isothiocyanate-labeled dextran into the cranial artery and monitored hepatic fluorescence by microscopy. The peripheries of the median and left lobes displayed decreased perfusion in regions corresponding to those regions that displayed necrosis at later developmental times. An examination of adult Ahr-/- animals revealed that smaller livers are predominantly due to decreased sizes of the left and right lobes, corresponding to regions of decreased perfusion and hepatic necrosis observed in fetal livers. Histological aberrations in the portal vein also support a model in which perfusion is compromised in the Ahr-/- liver. Taken in sum, these results indicate that the Ahr locus is required for normal perfusion of the developing liver and that disruption of the AHR signaling pathway gives rise to fetal hepatic necrosis and consequent liver deformation which persists through adult-hood.

Integrity signals

Registry

Crossref · 10.1124/mol.105.020107

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Hepatic phenotypes, including reduced liver size, hepatic portal fibrosis, neonatal hepatic steatosis, and reduced hepatocyte size, were also observed in Ahr null mice.

    “Hepatic phenotypes, including reduced liver size, hepatic portal fibrosis, neonatal hepatic steatosis, and reduced hepatocyte size, were also observed (Fernandez-Salguero et al., 1995; Harstad et al., 2006).”

    From Rodent Genetic Models of Ah Receptor Signaling (2021) · cites this paper as Harstad et al., 2006

  • Patent ductus venosus is among the most easily assessed and penetrant AHR-mediated phenotypes.

    “The patent DV is one of the most easily assessed and penetrant AHR-mediated phenotypes (Harstad et al., 2006; Lahvis et al., 2000; Lahvis et al., 2005).”

    From Rodent Genetic Models of Ah Receptor Signaling (2021) · cites this paper as Harstad et al., 2006

  • Ahr null mice show a patent ductus venosus with complete penetrance.

    “Mice null for Ahr exhibit a patent DV with 100% penetrance, though the AHR-driven genes responsible for shunt closer remain unknown.”

    From Rodent Genetic Models of Ah Receptor Signaling (2021) · cites this paper as Harstad et al., 2006

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Harstad, E. B., Guite, C. A., Thomae, T. L., & Bradfield, C. A.
Affiliations
University of Wisconsin–Madison (US)
Venue
Molecular Pharmacology
Publisher
Elsevier BV
Published
2006-05
Volume
69
Issue
5
Pages
1534-1541
ISSN
0026-895X (ISSN-L)
OpenAlex
W1976777279
Cited by
67
References
4
Citations by year
2025: 1 · 2024: 2 · 2022: 2 · 2021: 2 · 2020: 5 · 2018: 2 · 2017: 3 · 2016: 4 · 2015: 4 · 2014: 5 · 2013: 4
FWCI
4.21
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Cancer Institute (T32CA009681, P01CA022484, P30CA014520)
  • National Institute of Environmental Health Sciences (R01ES013566)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiovascular Conditions and Treatments
  • Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Toxic Organic Pollutants Impact
Keywords
aryl hydrocarbon receptor, liver perfusion, fetal liver development, liver deformation, liver necrosis, patent ductus venosus, AhR signaling pathway
MeSH terms
Animals, Crosses, Genetic, Female, Liver, Liver Circulation, Male, Necrosis, Perfusion, Pregnancy, Receptors, Aryl Hydrocarbon, Mice, Knockout, Embryonic Development, Mice, Basic Helix-Loop-Helix Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review